The UK MHRA has become the first regulator in the world to approve for marketing a subcutaneous (SC) version of Roche’s anti-PD-(L)1 cancer immunotherapy, Tecentriq (atezolizumab), which cuts treatment time by up to 75% compared with the intravenous (IV) infusion formulation.
Tecentriq SC is to be made available in England via the National Health Service, which today said it would be the “first health system in the